Inogen Inc (NASDAQ:INGN) – Equities researchers at Leerink Swann lowered their Q4 2018 earnings estimates for shares of Inogen in a report issued on Wednesday, November 7th. Leerink Swann analyst D. Antalffy now forecasts that the medical technology company will earn $0.25 per share for the quarter, down from their prior forecast of $0.48. Leerink Swann also issued estimates for Inogen’s Q1 2019 earnings at $0.19 EPS, Q2 2019 earnings at $0.60 EPS, Q3 2019 earnings at $0.74 EPS, FY2019 earnings at $2.17 EPS, Q1 2020 earnings at $0.07 EPS, Q2 2020 earnings at $0.57 EPS, FY2020 earnings at $2.00 EPS, FY2021 earnings at $2.44 EPS and FY2022 earnings at $2.87 EPS.
Several other analysts have also issued reports on the company. BidaskClub lowered Inogen from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 20th. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $290.00 target price on the stock in a report on Thursday, September 27th. Piper Jaffray Companies increased their target price on Inogen from $245.00 to $290.00 and gave the stock an “overweight” rating in a report on Wednesday, September 12th. Needham & Company LLC lowered Inogen from a “strong-buy” rating to a “buy” rating and increased their target price for the stock from $254.00 to $296.00 in a report on Monday, September 10th. Finally, Stifel Nicolaus set a $258.00 target price on Inogen and gave the stock a “buy” rating in a report on Tuesday, August 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $244.67.
Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.21. The company had revenue of $95.29 million for the quarter, compared to analyst estimates of $90.94 million. Inogen had a return on equity of 19.76% and a net margin of 12.28%. Inogen’s quarterly revenue was up 38.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.33 EPS.
A number of large investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC raised its position in Inogen by 162.5% in the third quarter. Advisory Services Network LLC now owns 525 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 325 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new position in Inogen in the third quarter valued at about $128,000. First Quadrant L P CA bought a new position in Inogen in the third quarter valued at about $134,000. Catalyst Capital Advisors LLC bought a new position in Inogen in the second quarter valued at about $112,000. Finally, Flagship Harbor Advisors LLC raised its position in Inogen by 1,090.9% in the third quarter. Flagship Harbor Advisors LLC now owns 655 shares of the medical technology company’s stock valued at $157,000 after purchasing an additional 600 shares during the last quarter. 96.67% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Raymond Huggenberger sold 10,500 shares of the firm’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $228.63, for a total value of $2,400,615.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Heath Lukatch sold 500 shares of the firm’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $261.54, for a total value of $130,770.00. Following the completion of the sale, the director now directly owns 4,239 shares in the company, valued at $1,108,668.06. The disclosure for this sale can be found here. Insiders sold 46,000 shares of company stock worth $11,098,610 over the last ninety days. 5.29% of the stock is currently owned by insiders.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also: Float
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.